INC Research Holdings Inc(NASDAQ:INCR) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $258.80M. Analysts estimated a revenue of $252.39M. Earnings per share were $0.61. Analysts had estimated an EPS of $0.57.
In a different note, Credit Suisse said it Initiates Coverage on INC Research Holdings Inc, according to a research note issued on Jun 21, 2016. The shares have been rated ‘Outperform’ by the firm.
INC Research Holdings Inc (INCR) made into the market gainers list on Thursdays trading session with the shares advancing 0.97% or 0.43 points. Due to strong positive momentum, the stock ended at $44.95, which is also near the day’s high of $45.34. The stock began the session at $44.66 and the volume stood at 5,90,541 shares. The 52-week high of the shares is $57.11 and the 52 week low is $34.19. The company has a current market capitalization of $2,459 M and it has 5,47,05,984 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jul 18, 2016, Gregory S Rush (Executive VP and CFO) sold 5,917 shares at $41.50 per share price.Also, On Jul 12, 2016, Alistair Macdonald (Chief Operating Officer) sold 9,468 shares at $40.19 per share price.On Jul 12, 2016, Christopher L Gaenzle (CAO, GC & Sec) sold 21,918 shares at $40.21 per share price, according to the Form-4 filing with the securities and exchange commission.
INC Research Holdings Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company’s segment Clinical Development Services offers a variety of clinical development services including global studies clinical monitoring investigator recruitment patient recruitment data management and study reports. The Company’s segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Company’s segment Global Consulting provides consulting services regarding clinical trial regulatory affairs regulatory consulting services quality assurance audits and pharmacovigilance consulting non-clinical consulting and medical writing consulting.